The forecast for non-steroid anti-inflammatory and antirheumatic medicine sales in Canada shows a declining trend from 2024 to 2028, with per capita values decreasing from 5.2 in 2024 to 4.9 in 2028. The decrease from 2024 to 2028 indicates an annual average drop of approximately 1.5%, reflecting a gradual reduction in demand or consumption per capita. The decline in annual sales per capita might reflect market saturation or shifts in consumer preferences toward alternative therapies.

Future trends to watch for include:

Potential impact of new pharmaceutical innovations disrupting the traditional anti-inflammatory market.
Regulatory changes affecting drug pricing or availability could influence sales.
Increased focus on personalized medicine and alternative treatments.